Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 4;12(2):27.
doi: 10.3390/antib12020027.

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors

Paolo Alimonti  1 , L Nicolas Gonzalez Castro  2
Affiliations
Review

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors

Paolo Alimonti et al. Antibodies (Basel). .

Abstract

Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we discuss the available evidence for the use of ICIs in the treatment of primary and metastatic brain tumors, highlighting challenges and opportunities for furthering this type of cancer immunotherapy in neuro-oncology.

Keywords: IDH-mutant gliomas; brain metastasis; glioblastoma; immune checkpoint inhibitors; meningiomas; primary CNS Lymphoma.

PubMed Disclaimer

Conflict of interest statement

L.N.G.C. has received research funding from Merck & Co. (to the Dana-Farber Cancer Institute).

Figures

Figure 1
Figure 1
Immune checkpoint inhibition of T cell function via CTLA-4 and PD-1. CTLA-4: cytotoxic T-lymphocyte-associated protein 4. PD-1: programmed cell death protein 1. PD-L1/2: programmed death ligand 1/2. APC: Antigen presenting cell. TCR: T cell receptor. pMHC: peptide MHC complex. MHC: major histocompatibility complex.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wei S.C., Duffy C.R., Allison J.P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069–1086. doi: 10.1158/2159-8290.CD-18-0367. - DOI - PubMed
    1. Twomey J.D., Zhang B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021;23:39. doi: 10.1208/s12248-021-00574-0. - DOI - PMC - PubMed
    1. Rossi E., Schinzari G., Maiorano B.A., Indellicati G., Di Stefani A., Pagliara M.M., Fragomeni S.M., De Luca E.V., Sammarco M.G., Garganese G., et al. Efficacy of immune checkpoint inhibitors in different types of melanoma. Hum. Vaccin. Immunother. 2021;17:4–13. doi: 10.1080/21645515.2020.1771986. - DOI - PMC - PubMed
    1. Berghmans T., Durieux V., Hendriks L.E.L., Dingemans A.M. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. Front. Med. 2020;7:90. doi: 10.3389/fmed.2020.00090. - DOI - PMC - PubMed
    1. Tomaszewski W., Sanchez-Perez L., Gajewski T.F., Sampson J.H. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin. Cancer Res. 2019;25:4202–4210. doi: 10.1158/1078-0432.CCR-18-1627. - DOI - PMC - PubMed

LinkOut - more resources